Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Journal of Multidisciplinary Healthcare
|
January 5, 2023
Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group
Lingcan Tan, Yi Teng, Hong Yu, et al.
Journal of Chromatography. A
|
October 28, 2018
Thin layer chromatography combined with surface-enhanced raman spectroscopy for rapid sensing aflatoxins
Lu-Lu Qu, Qin Jia, Chunyuan Liu, et al.
Journal of Multidisciplinary Healthcare
|
January 24, 2023
The Knowledge Profile, Competence and Pending Problems of Chinese Anesthesiologists in Dealing with Malignant Hyperthermia: A Cross-Sectional Survey
Lingcan Tan, Hong Yu, Junyu Yan, et al.
Frontiers in Medicine
|
August 20, 2025
A multidimensional comparison of the benefit degrees for patients between ileostomy and colostomy
Yuhang Wang, Lei Cheng, Weichao Li, et al.
Journal of the American Academy of Dermatology
|
November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.
Dermatology and Therapy
|
January 29, 2025
Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch
Matthias Augustin, Maddalena Napolitano, Rosa Izu-Belloso, et al.
Advances in Therapy
|
June 18, 2023
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
Jacob P Thyssen, Marjolein de Bruin-Weller, Antonio Costanzo, et al.
Journal of the American Academy of Dermatology
|
October 24, 2024
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2
Brett King, Manabu Ohyama, Maryanne Senna, et al.
JAMA Dermatology
|
August 14, 2024
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial
Brett King, Justin Ko, Ohsang Kwon, et al.
Dermatology and Therapy
|
May 22, 2024
Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
José-Manuel Carrascosa, Alessandra Narcisi, Toshifumi Nomura, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Journal of Multidisciplinary Healthcare
|
January 5, 2023
Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group
Lingcan Tan, Yi Teng, Hong Yu, et al.
Journal of Chromatography. A
|
October 28, 2018
Thin layer chromatography combined with surface-enhanced raman spectroscopy for rapid sensing aflatoxins
Lu-Lu Qu, Qin Jia, Chunyuan Liu, et al.
Journal of Multidisciplinary Healthcare
|
January 24, 2023
The Knowledge Profile, Competence and Pending Problems of Chinese Anesthesiologists in Dealing with Malignant Hyperthermia: A Cross-Sectional Survey
Lingcan Tan, Hong Yu, Junyu Yan, et al.
Frontiers in Medicine
|
August 20, 2025
A multidimensional comparison of the benefit degrees for patients between ileostomy and colostomy
Yuhang Wang, Lei Cheng, Weichao Li, et al.
Journal of the American Academy of Dermatology
|
November 28, 2025
Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
Maryanne Senna, Arash Mostaghimi, Rodney Sinclair, et al.
Dermatology and Therapy
|
January 29, 2025
Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch
Matthias Augustin, Maddalena Napolitano, Rosa Izu-Belloso, et al.
Advances in Therapy
|
June 18, 2023
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
Jacob P Thyssen, Marjolein de Bruin-Weller, Antonio Costanzo, et al.
Journal of the American Academy of Dermatology
|
October 24, 2024
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2
Brett King, Manabu Ohyama, Maryanne Senna, et al.
JAMA Dermatology
|
August 14, 2024
Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial
Brett King, Justin Ko, Ohsang Kwon, et al.
Dermatology and Therapy
|
May 22, 2024
Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
José-Manuel Carrascosa, Alessandra Narcisi, Toshifumi Nomura, et al.
Page
of 4